ID# 1939: Bioconductance Scanning Technique and Patient Safety/Acceptability in Subjects with Indeterminate Masses by Lung CT

RC Yung, MD1, M. Zeng, MD1, M. Garff2, KS Callahan, PhD2 --- 1Johns Hopkins University, Baltimore, MD, USA and 2Freshmedx, Salt Lake City, UT, USA

Introduction
- The bioconductance properties of cancerous tissue vary significantly from those of normal and benign tissue.
- Freshmedx’s non-invasive proprietary Computerized Bioconductance (CB) scan demonstrates immediate results in differentiating between benign and malignant lesions in the lung (Poster #1908).
- Recent studies suggest CT screening is useful in assessing individuals at high risk of lung cancer, but CT produces high numbers of indeterminate lesions.1,2 Due to difficulties associated with lung biopsy, repeat CT scanning is most often utilized to establish risk of cancer. Repeat CT scanning exposes patients to additional radiation and anxiety from waiting for CT confirmation.

Technique
- 1.5 days of training establishes operator proficiency of the testing protocol.
- The operator places the diaphoretic electrodes on the patient’s back and hands.
- The screen prompts the operator for all anatomical locations around the shoulders and chest, and the device delivers a safe current below 25 micro amps to measure tissue bioconductivity between the probe and electrodes.
- The CB technique using the Freshmedx Bioconductance Scan Platform (BSP):
  A. Is non-invasive
  B. Is easy-to-use
  C. Provides immediate evaluation of suspicious lesions
  D. Requires no specimen handling
  E. Has high patient acceptability
  F. Is highly reliable and repeatable
  G. Does not expose patient to known risks

Patient Safety/Acceptability
- Following testing (poster #1908), 55 patients answered the following questions:
  1) Did measurement cause discomfort? One patient noted “a little pressure.”
  2) Did test duration seem reasonable? All responded that the test time was acceptable.
  3) Would you undergo measurement again? All but three patients responded “yes” to undergoing repeated measurement, one of which responded “maybe,” one of which provided no reason for the negative response, and one of which cited excessive travel time.
- No Adverse Events documented.
- BSP complies with the IEC 60601-1-1, 60601-1-2 medical electrical equipment safety standards, which are recognized by the FDA and European MDD 93/42/EEC, and has obtained the CE Mark.

References
2www.cancer.gov/cancertrials/noteworthy-trials.nlst

Conclusions
- The CB technique using the Freshmedx Bioconductance Scan Platform (BSP):
  A. Is non-invasive
  B. Is easy-to-use
  C. Provides immediate evaluation of suspicious lesions
  D. Requires no specimen handling
  E. Has high patient acceptability
  F. Is highly reliable and repeatable
  G. Does not expose patient to known risks
- Freshmedx’s Bioconductance Scan Platform is a therapy-enabling technology that can evaluate indeterminate lung lesions.

www.freshmedx.com . 757 E South Temple, Ste 150 . Salt Lake City, UT 84102 USA

Steven C. Eror  
President and CEO  
sce@freshmedx.com  
801.736.0729

Rex C. Yung  
Investigator  
ryung@jhmi.edu